Therefore, plasma F-circEA may serve as a liquid biopsy biomarker to diagnose NSCLC patients with EML4-ALK translocation and guide the targeted therapy for NSCLC patients in this subgroup (129). This evidence concerns the gene ALK and non-small cell lung carcinoma.